UTMDHealthcare · Medical Instruments & SuppliesTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 12 Oct 2026 — inside the top quartile.
Consensus tells you what everyone already believes. The model scores Utah Medical Products, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (98): The share price has been relatively steady.
Revisions (25): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on UTMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. UTMD appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 12 Oct 2026, Utah Medical Products, Inc. returned +23.7% against +20.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 33% of US stocks
Cheaper than 19% of US stocks
Cheaper than 45% of US stocks
Cheaper than 36% of US stocks
Higher than 13% of US stocks
Higher than 25% of US stocks
Higher than 69% of US stocks
Higher than 90% of US stocks
Higher than 88% of US stocks
Higher than 60% of US stocks
Higher than 82% of US stocks
Higher than 76% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Utah Medical Products, Inc. has a market value of $236.6M and an enterprise value of $146.5M.
Revenue in the twelve months to 30 June 2026: $36.1M. The latest quarter shrank 14.3% year on year.
Net income over the same four quarters: $10.5M, a 29.0% net margin.
Diluted earnings per share, trailing twelve months: $3.28.
Free cash flow in the twelve months to 30 June 2026: $11.4M.
Utah Medical Products, Inc. spent $1.9M on share buybacks and $3.9M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 22.5×.
Forward dividend yield: 1.66%, paying out 38% of earnings.
Utah Medical Products, Inc. employs 140 people — $258K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Utah Medical Products, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks says Utah Medical Products’ Orion acquisition, strong cash reserves, improving margins and product expansion efforts support its growth prospects and continued shareholder returns.
Why it matters — These factors are relevant to UTMD watchers assessing the company’s business outlook and shareholder-return context.
Utah Medical Products, Inc. (Nasdaq:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The tender offer, initially scheduled to expire at 5:00 p.m. on October 5, 2026, has been extended.
Why it matters — The extension affects the timeline for UTMD shareholders considering participation in the company's share buyback offer.
Utah Medical Products, Inc. announced details of a tender offer to purchase up to 650,000 shares of its common stock at $75.00 per share, as outlined in its SEC Form TO filing. The offer is scheduled to expire at 5:00 p.m., and the company clarified this expiration date in the announcement.
Why it matters — UTMD watchers would care because the clarified tender offer expiration date affects the timeline for shareholders deciding whether to participate in the share repurchase.
Utah Medical Products, Inc. commenced a tender offer to purchase up to 650,000 shares of its common stock at $75.00 per share. The offered price represents a 17% premium over the average daily closing price over the last twelve months and a 21% premium over the last twenty-four months.
Why it matters — The buyback at a premium above recent average trading prices signals management's confidence in the company's value and could be relevant to shareholders considering the tender offer.
Utah Medical Products, Inc. announced a self-tender offer to repurchase up to 650,000 of its shares, approximately 20% of its outstanding shares, at $75.00 per share, with tenders due by October 7. The offering price is 17% higher than the average daily closing price over the past year and 21% higher than over the past two years.
Why it matters — A significant self-tender at a premium to recent market prices signals management's confidence in the company's value and offers stockholders a potential opportunity to sell shares at above-market prices.
As at 12 Oct 2026, Utah Medical Products, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).
No analyst covering Utah Medical Products, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UTMD are extrapolating price history, which says nothing about the business.
Utah Medical Products, Inc. returned +23.7% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Utah Medical Products, Inc. is a medical device company that develops, manufactures, and markets specialized disposable and reusable products for healthcare settings.
The most recent item we track (Zacks Investment Research, 8 Oct 2026): "UTMD Trades at a Premium to the Industry: How to Play the Stock?". Zacks says Utah Medical Products’ Orion acquisition, strong cash reserves, improving margins and product expansion efforts support its growth prospects and continued shareholder returns.
Utah Medical Products, Inc. is a medical device company that develops, manufactures, and markets specialized disposable and reusable products for healthcare settings. The company focuses on women’s and babies’ health, with offerings used in obstetrics, gynecology, neonatal care, perinatology, urology, blood pressure monitoring, and blood collection. Its product portfolio includes labor and delivery tools, fetal monitoring accessories, vacuum-assisted delivery systems, infant respiratory hoods, and electrosurgical devices. Utah Medical Products serves hospitals, clinics, and other medical facilities that require procedure-specific devices designed for clinical use and patient safety. Headquartered in Midvale, Utah, the company operates as a focused supplier within the broader medical instruments and supplies market, with products distributed across domestic and international healthcare markets.
CEO Mr. Kevin L. Cornwell · 140 employees · United States · https://www.utahmed.com
